Shanghai Fosun Pharmaceutical (Group) (HKG:2196, SHA:600196) agreed to sell a total equity stake of 55% in Shanghai Fujian Equity Investment Fund Management to three parties for around 26.5 million yuan, an April 11 filing with the Hong Kong bourse said.
Of this, 29%, 25.9% and 0.1% equity interests were sold to controlling shareholder Shanghai Fosun High Technology (Group), Li Fan, and executive director Guan Xiaohui for around 14 million yuan, 12.5 million yuan, and 48,254 yuan, respectively.
Following completion, the company holds a 45% equity stake in the target company, which engages mainly in equity investment management, investment management, and investment consultancy.
The pharmaceutical firm will use proceeds from the sale for working capital.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。